
United Kingdom · Medical devices startup
Leo Cancer Care is a healthcare technology company based in Horley, Surrey, UK, founded in 2014.
Follow Leo Cancer Care and see its new rounds in your feed.Sign up free
Funding reportedLast round: Series C
Leo Cancer Care is a healthcare technology company based in Horley, Surrey, UK, founded in 2014.
The company focuses on patient-centric radiotherapy solutions, emphasizing upright patient positioning to enhance treatment outcomes and comfort. This innovative approach allows patients to be treated in an upright position, which reduces anxiety and improves the integration of imaging during therapy. The company offers a range of products, including the MarieTM for upright particle therapy and the RubyTM for photon therapy, both designed to optimize treatment precision and reduce facility costs. Leo Cancer Care's technology can significantly lower capital expenses for proton therapy centers, making it easier for healthcare facilities to implement advanced radiotherapy solutions. Their systems also feature advanced 3D imaging capabilities to ensure accurate dose delivery. Leo Cancer Care serves a global market, targeting cancer treatment centers, proton therapy facilities, and medical device manufacturers. The company collaborates with various partners, including TibaRay, Inc., to develop next-generation radiotherapy technologies. Their mission is to improve the quality of care by delivering radiation therapy in a more human-centered way.
Funding, as reported
From Leo Cancer Care's own website: 1 founder, 13 on the team.
What they build
Known for
medical equipment manufacturinghospital & health careupright radiotherapycancer treatmentmedical devicesphoton therapyb2bproton therapy
Built with from their website
Google Tag ManagerWordPress.orgPWAVLANC/C++C++YouTubeGemViewport MetaSite Kit
CookieYesESETNetSuiteSplit HeroYardi Commercial SuiteSalesforce Marketing Cloud IntelligenceOWL CarouselPriority Hints
Add your raise, your deck and your story, and put Leo Cancer Care in front of investors. Or tell us what we have wrong.